ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19
(2020) In Journal of Law, Medicine & Ethics 48(3). p.579-582- Abstract
- There is no doubt that COVID-19 will have a substantial impact on access to biologics and biosimilar uptake, as well as on the related ethical, legal, and social dimensions of prioritization decisions. This holds especially true for Denmark and European markets, where governments are expected to cover most of the pharmaceutical needs of their citizens and where the crisis has been leading to an important reduction of available resources. In this paper we make four key comments relating to (1) broader ethico-legal dimensions of prioritizations in Europe, (2) human rights law and (3) regulatory aspects of access, diversification, vulnerability and systemic trust, and (4) additional challenges posed by COVID-19.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/6db777f6-50fe-427e-bce7-879889422a34
- author
- Druedahl, Louise C. ; Lebret, Audrey and Minssen, Timo LU
- publishing date
- 2020-10-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Medical law, Medicinsk rätt
- in
- Journal of Law, Medicine & Ethics
- volume
- 48
- issue
- 3
- pages
- 4 pages
- publisher
- SAGE Publications
- external identifiers
-
- scopus:85092356937
- pmid:33021187
- ISSN
- 1073-1105
- DOI
- 10.1177/1073110520958884
- project
- The Quantum Law Project
- language
- English
- LU publication?
- no
- id
- 6db777f6-50fe-427e-bce7-879889422a34
- date added to LUP
- 2020-12-16 13:11:14
- date last changed
- 2022-04-19 02:45:47
@article{6db777f6-50fe-427e-bce7-879889422a34, abstract = {{There is no doubt that COVID-19 will have a substantial impact on access to biologics and biosimilar uptake, as well as on the related ethical, legal, and social dimensions of prioritization decisions. This holds especially true for Denmark and European markets, where governments are expected to cover most of the pharmaceutical needs of their citizens and where the crisis has been leading to an important reduction of available resources. In this paper we make four key comments relating to (1) broader ethico-legal dimensions of prioritizations in Europe, (2) human rights law and (3) regulatory aspects of access, diversification, vulnerability and systemic trust, and (4) additional challenges posed by COVID-19.}}, author = {{Druedahl, Louise C. and Lebret, Audrey and Minssen, Timo}}, issn = {{1073-1105}}, keywords = {{Medical law; Medicinsk rätt}}, language = {{eng}}, month = {{10}}, number = {{3}}, pages = {{579--582}}, publisher = {{SAGE Publications}}, series = {{Journal of Law, Medicine & Ethics}}, title = {{ELSI Implications of Prioritizing Biological Therapies in the Times of COVID-19}}, url = {{http://dx.doi.org/10.1177/1073110520958884}}, doi = {{10.1177/1073110520958884}}, volume = {{48}}, year = {{2020}}, }